Immunome (NASDAQ:IMNM) Reaches New 52-Week Low – Should You Sell?

Immunome, Inc. (NASDAQ:IMNM) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $8.12 and last traded at $8.15, with a volume of 960264 shares traded. The stock had previously closed at $8.18.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Stephens restated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Guggenheim cut their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome currently has an average rating of “Buy” and an average price target of $25.50.

Immunome Trading Down 0.4 %

The firm has a market capitalization of $708.65 million, a P/E ratio of -1.00 and a beta of 1.93. The stock has a 50-day simple moving average of $9.72 and a two-hundred day simple moving average of $11.49.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. As a group, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This represents a 28.87 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new position in shares of Immunome in the 4th quarter worth $70,000. KLP Kapitalforvaltning AS purchased a new position in Immunome in the fourth quarter valued at about $75,000. AlphaQuest LLC grew its stake in Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome in the 4th quarter valued at about $95,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.